IQVIA Holdings Inc. $IQV Stock Position Raised by Pallas Capital Advisors LLC

Key Points

• Pallas Capital Advisors LLC significantly increased its stake in IQVIA Holdings Inc. by 113.2% during the second quarter, now owning 12,000 shares valued at approximately $1.89 million.
• Insider selling was reported, with key insiders like Keriann Cherofsky and Eric Sherbet divesting shares, leading to decreases in their holdings by 15.87% and 17.59% respectively.
• IQVIA's recent quarterly earnings of $2.81 per share exceeded analysts' expectations, marking a 5.3% year-over-year revenue growth, with full-year guidance set at $11.750-12.050 EPS.

Pallas Capital Advisors LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 113.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,000 shares of the medical research company's stock after purchasing an additional 6,371 shares during the quarter. Pallas Capital Advisors LLC's holdings in IQVIA were worth $1,891,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. American National Bank & Trust purchased a new stake in shares of IQVIA during the first quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC grew its position in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. grew its holdings in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IQV shares. UBS Group increased their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Mizuho lifted their price objective on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. William Blair restated an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 target price on IQVIA in a research note on Wednesday, September 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $229.64.

IQVIA Price Performance

Shares of IQV stock traded down $2.91 during trading hours on Friday, reaching $187.29. 2,104,117 shares of the company were exchanged, compared to its average volume of 1,124,593. The stock's fifty day moving average is $184.79 and its two-hundred day moving average is $167.31. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $245.20. The company has a market cap of $31.84 billion, a price-to-earnings ratio of 27.10, a P/E/G ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.